Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis

Table 3

Response rates.

	CR	PR	SD	PD	NE
First line
Doxorubicine (n = 15)	0/15	2/15	4/15	7/15	2/15
Consecutive lines
Pazopanib (n = 9)	0/9	4/9	2/9	2/9	1/9
Ifosfamide (n = 5)	0/5	0/5	0/5	4/5	1/5
Dacarbazine (n = 2)	0/2	0/2	1/2	1/2	0/2
Trabectedin (n = 3)	0/3	0/3	2/3	1/3	0/3

CR: complete response PR: partial response, SD: stable disease, PD: progressive disease, NE: not evaluable or available. Patients treated with pazopanib (n = 9) in second (n = 5) and third line (n = 4) were pooled for this analysis. Best response per single-agent systemic therapy and per treatment line according to treating physician.